122 results about "Thymopentin" patented technology

The invention discloses a thymopeptide-5 powder preparation and a preparation method thereof. The method comprises the following steps: dissolving excipient in water to produce solution I, and filtering the solution I to collect filtrate I; adding the thymopeptide-5 to the filtrate I to obtain solution II, and filtering solution II to collect filtrate II; and freezing and drying the filtrate II to obtain the thymopeptide-5 powder preparation. The excipient can be any one of mannite, lactose and glycin. Experiments prove that, in the thymopeptide-5 powder preparation, thymopeptide-5 is not easy to be degraded, and has good solubility; low content of 'related substances' which is below 1.0 percent, so that healing efficacy and safety of the thymopeptide-5 powder preparation can be greatly improved.

A polyglycolized derivative of thymopeptide-5, which can be used to prepaer the medicines for preventing and treating rheumatoid arthritis, allergic dermatisis, tumor, viral infection, and the diseases associated with immune deficiency and hypoimmunofunction, is disclosed. Said derivative features that the polyglycol, polyglycol modified amino acid, cysteine, maleamido glycol, vinyl glycol, or iodoacetylglycol is introduced or coupled to the N or C terminal of thymopeptide-5.

The present invention relates to a prescription of thymus pentapetide injection. Said prescription includes 1-100 mg of thymus pentapeptide, 0-100 mg of anhydrous sodium acetate, 0-50 mg of citric acid, 300-1000 mg of sodium chloride and 0.2-5 ml of injection water. Said thymus pentapeptide injection can be made into ampule package form.

The invention relates to a medicinal composition containing a thymopentin compound, and in particular relates to an injection as well as a formula, application and a preparation method thereof. Each 1,000 injections are prepared from the following components: 0.5 to 2g of thymopentin, 50 to 200g of mannitol, 1 to 3g of ethylene diamine tetraacetic acid (EDTA) calcium, 1 to 2g of vitamin C, 1,000ml of buffer solution of disodium hydrogen citrate and trisodium citrate at a mole ratio of 1: 4, and the balance of injection water to the volume of 2,000ml.

The invention relates to a medicinal preparation and a preparation method thereof, and in particular relates to a series of polypeptide thymopentin, thymalfasin and thymosin beta4 combined enzyme inhibitors capable of improving the immunity. An oral preparation is prepared by adopting a nanoparticle technology. A pharmaceutically-acceptable biodegradable high polymer material is coated with a polypeptide medicament for improving the immunity to prepare nanoparticles, and tablets are made by tableting. The medicament-loading nanoparticles prepared by using the preparation method have high bioavailability.

The invention belongs to the field of medical preparations, and relates to an immunomodulator polypeptide slow-release microsphere preparation and a preparation method thereof. Particularly, the immunomodulator polypeptide comprises thymopentin, thymalfasin and thymosin beta4. The slow-release microsphere comprises 0.1-30% (w/w) of immunomodulator polypeptide, 60-80% of biodegradable high polymer material with biocompatibility, of which the molecular weight is 5,000-200,000 Dalton, and 0.1-20% of other pharmaceutical acceptable auxiliary materials on the basis of the total weight of the microsphere. According to the slow-release microsphere disclosed by the invention, the mean grain size is 5-60mu m; the encapsulation efficiency is greater than 90%; the slow release period of the slow-release microsphere can be up to a few days and months, the medication times is obviously reduced, the bioavailability is improved, the toxic and side effects of the medicine are reduced, and clinical treatment is facilitated. The product is good in production process repeatability and good in feasibility.

The invention relates to a drug composition of thymopentin composed of five kinds of amino acids. The drug composition can improve immunity and cure diseases such as hepatitis, deficiency of T lymphocytes and autoimmune diseases, and contains, by weight, 1-10 parts of thymopentin composed of five kinds of amino acids, 0.4-0.6 part of citric acid, 1.4-1.6 parts of dipotassium phosphate and 48-52 parts of glucose. The preparation method includes adding the citric acid, the dipotassium phosphate and the glucose into water for injection to dissolve; adding thymopentin to dissolve with stirring and then stirring evenly, adding active carbon for injection and stirring, filtering for decarburization, and obtaining a filter solution through filter membrane filtration sterilization; and obtaining the drug composition of the thymopentin through filter solution subpackaging or freeze drying. Prepared thymopentin for injection and thymopentin injection have good quality and stability, and can maintain a high stability even at a room temperature and be stored for more than 36 months.

The invention relates to a nasal spraying agent of thymopentin, and a preparation method and applications thereof. The preparation is used in over18-year-old sufferers of chronic hepatitis B, various primary or secondary defect diseases of T cellular, certain autoimmune diseases, various diseases of low cellular immune function and adjutant therapy to tumours; the preparation consists of thymopentin, pharmaceutic adjuvant and water; the preparation method of the agent includes the steps of liquid preparation, degerming, split charging, stoppering, capping, package, etc. The medicament form overcomes the difficulty that polypeptide drugs are unsteady in water, thus keeping the activity of thymopentin well and having good stability; meanwhile, pain is not produced when the medicament form is used, thus being accepted by the general consumers.

The invention relates to an immunomodulator thymopentin powder injection pharmaceutical composition and a quality control method. The immunomodulator thymopentin powder injection pharmaceutical composition comprises thymopentin, mannitol and an optional acid or alkali modulator, wherein the mannitol is 20-100 parts by weight on the basis of each 100 parts by weight of thymopentin. The thymopentin pharmaceutical composition can be used for treating chronic viral hepatitis, such as chronic hepatitis B and can be used for treating various primary or secondary T cell defects such as congenital immunodeficiency in children. In addition, the immunomodulator thymopentin powder injection pharmaceutical composition can be used for treating a few of autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus, can be used for treating various diseases caused by a low cellular immune function, and can also be used for tumor treatment, especially adjuvant treatment of tumors. The immunomodulator thymopentin powder injection pharmaceutical composition has an excellent technical effect.

The invention provides a prescription and a preparation method of a thymopeptide-5 injection for treating chronic disease toxic hepatitis, tumor, and other immunity diseases. The injection is prepared through taking thymopeptide-5 as an active ingredient, and adding injection-use auxiliary materials and injection-use water. The invention aims to overcome the shortages of pharmaceutical preparations taking thymopeptide-5 as the active ingredient, and provides the prescription and the preparation method of the thymopeptide-5 injection. The thymopeptide-5 injection provided by the invention has stable stability and convenience in preparation, reduces contamination rate during the use of medication, provides great convenience to the use of the medication, and improves the safety of the medication and adaptability of patients.

The invention discloses an Fmoc-strategy solid-phase synthesis method of thymopentin. The method comprises the following steps: taking Fmoc protected amino acids as the monomers and sequentially connecting the amino acids to a resin, wherein while synthesizing pentapeptide, the solvent of the added amido acid Fmoc-Arg(Pbf)-OH solution is the mixed solution of DMF (Dimethyl Formamide) and THF (Tetrahydrofuran); depriving all Fmoc protecting groups by using a piperazine solution, and finally, removing the resin and the side chain protecting groups to obtain the thymopentin. According to the invention, the piperazine is taken as the deprotection agent for depriving Fmoc in stead of the traditional pyridine, and the piperazine is a substance unregulated as the dangerous chemical and the poison-making chemical, and is cheap and easy to get, and also stable in chemical properties; the piperazine is in the form of white acicular crystals at the normal temperature, while piperidine is a liquid at the normal temperature, and therefore, the piperazine is more convenient to transport and store; under the same concentration, the Fmoc depriving efficiency of the piperazine is higher than that of piperidine; and obviously, the piperazine has many advantageous in the synthesis of the thymopentin, and also has great stimulative significance in production and study of polypeptides.

The invention relates to a frontal polymerization preparation method for a thymopentin molecular imprinted hydrogel which is prepared from the raw materials in percentage by mass: 4.33%-11.94% of thymopentin, 10.00%-36.44% of N-isopropylacrylamide, 5.88%-21.86% of acrylic acid, 0.36%-0.74% of N, N'-methylenebisacrylamide, 9.92%-33.58% of choline chloride and 30.12%-53.68% of ethylene glycol. By using the frontal polymerization preparation method, a molecular imprinted hydrogel sustained-release material is prepared by taking bioactive molecule thymopentin as a template and a green solvent DESsystem as a pore-foaming agent, and the molecular imprinted hydrogel sustained-release material serving as a drug carrier is stable in physical and chemical properties and obvious in imprinting effect; the molecular imprinted hydrogel sustained-release material is large in drug loading capacity and has an obvious sustained-release effect for the template molecule thymopentin; and compared with a thermal polymerization imprinted hydrogel, the molecular imprinted hydrogel sustained-release material is capable of prolonging the in-vivo metabolism time of a drug and increasing the biological availability of the drug.

The invention relates to the field of medicine, and especially relates to an application of thymopentin in preparing medicine used for treating mastitis. As a result of subclinical mastitis efficacy test, infection mammary area numbers of thymopentin treatment groups, especially a high dose (4mg) group, have a reduction tendency after treatment. As a result of clinical mastitis efficacy test, through injection of thymopentin (TP-5) in breast lymph node for continuously 3 days, milk SCC of two TP-5 dose groups (10mg and 20mg) both have reduction tendencies, and cow breast swellings are substantially ameliorated in appearance. Therefore, medicines prepared with high-dose thymopentin (higher than 10mg) have significant effects against cow clinical mastitis. Therefore, the medicines prepared by using thymopentin have significant effects against subclinical mastitis and/or clinical mastitis.

The invention relates to a soluble thymopentin microneedle and a preparation method thereof. The soluble thymopentin microneedle comprises a needle tip and a substrate, wherein the needle tip is prepared from a water solution of a biodegradable material, bovine serum albumin and thymopentin in a mass ratio of 25 to (3-15) to (0.5-15); and the biodegradable material is selected from at least one of dextran, polyvinylpyrrolidone, polyvinyl alcohol, hyaluronic acid, carboxymethylcellulose and dihydrate-D-trehalose. By adding the bovine serum albumin into the needle tip material to prepare the soluble thymopentin microneedle, the mechanical strength of the needle tip can be improved, so that the problems that the needle tip of an existing soluble thymopentin microneedle is low in mechanical strength and a percutaneous drug delivery pore cannot be formed are effectively solved; and by adding the bovine serum albumin, the drug carrying quantity of a drug in the needle tip can be further increased, and the drug content of the needle tip part of the microneedle can be effectively increased.

The invention discloses a long-effective implantation agent of thymic pentapeptide in the drug agent domain, which is characterized by the following: adopting thymic pentapeptide as treating active material and biologically decomposed material as base; making the appearance as fine rob shape or cylinder shape; injecting or surgerying to transplant into body; releasing drug completely without surgery and fetching; obtaining high-packing rate and drug-carrying quantity to approach constant speed to release one to several months; reducing the medical cost; improving the compliance for patients. The invention has simple preparing technique and high safety, which projects he clinical treatment superiority and good applying prospect.

The invention relates to a liquid-phase synthesis method of thymopentin (TP-5) based on polyarylphosphorus or phosphoroxyphenylcarbinol (POB) compounds and their derivatives and auxiliary groups, comprising the following steps: a phosphorus or phosphite carrier replaces solid phase resin to be connected with the C- end of Fmoc-protected tyrosine under the action of a coupling dehydrant; N-end Fmocis removed after separation and purification; coupling with Fmoc, valine with side chain protection, asparaginic acid, lysine and arginine and Fmoc removal reaction are carried out to prepare a precursor C of thymopentin; and side chain is deprotected and the carrier is cleaved to obtain a solid of thymopentin. Compared with existing synthetic methods, the synthesis method of the invention has the advantages of liquid-phase and solid-phase synthesis, and can be adopted for simpler, faster, economical, efficient and large-scale synthesis of thymopentin. The POB auxiliary groups can be recovered and directly reused, raw material waste is reduced, waste pollution is lowered, costs are saved, and the method is good for environmental protection.

This invention is about the synthesis of thymic-pentapeptide. Using tyrosine and its derivative as raw material, after four condensation reactions, we add valine with tertiary-butyl or tertiary-butyl ketonic oxygen group protection, aspartate, lysine, and arginine accordingly to obtain protected pentapeptide. With the method we reported here, the all protection groups could be removed once to obtain targeted products, due to our adoption of tertiary-butyl ketonic oxygen group protection strategy. The method is advantageous in simplified procedure, high yield, cost cutting and high purity.